Overview

• CSL will eliminate nearly 3,000 roles — about 15% of its roughly 30,000 staff — targeting roughly $550 million in annual savings over the next three years.
• The company will combine commercial and medical operations across its plasma and iron‑deficiency businesses into a single unit while continuing to focus on rare and serious diseases.
• Management plans to separate the influenza‑vaccine arm, Seqirus, as a stand‑alone ASX‑listed company, with timing yet to be finalized.
• The proposed separation remains contingent on third‑party consents, regulatory approvals, plus a voluntary shareholder vote.
• CSL reported a 14% rise in underlying profit to US$3.3 billion, while its shares fell about 8% at the market open following the announcement.